LGVN
Longeveron Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.75
−1.69%Year over year
Reported trailing growth
- Revenue
- -42.7%
- EBITDA
- -27.2%
- EBIT
- -21.3%
- EPS
- —
- Free cash flow
- -34.4%
- Operating cash flow
- -40.4%
Forward estimates
Based on analyst estimates
- Revenue
- +15.4%
- EBITDA
- +39.6%
- EPS
- +54.0%
Three-year CAGR
- Revenue
- -0.6%
- EBITDA
- -43.0%
- EBIT
- -40.9%
- Net income
- -42.1%
- EPS
- -20.6%
- Free cash flow
- -27.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026